ACHE and Alzheimer disease: Some argue for attenuation of the disease process under treatment with AChE inhibitors [4], [5]; others develop alternative AD therapeutics, including inhibitors of the Tau kinase, Glycogen Synthase Kinase 3 (GSK3) [6], [7], or of other key proteins of the apoptotic pathway, but it is still unclear if these different approaches reflect a single targeted cascade and if so, what triggers this cascade.